Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + rituximab in marginal zone lymphoma with primary Sjögren's syndrome
ChiCTR2600121587Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib and rituximab in marginal zone B-cell lymphoma (MZL) and primary Sjögren's syndrome, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: objective response rate, ORR. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
orelabrutinibrituximab
03
Conditions
marginal zone B-cell lymphoma (MZL)primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2600121587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121587.